Peripherally Inserted Central Catheters Market - By Product (Power Injected PICC, Conventional PICC, Neonatal PICC), Lumen (Single, Double, Multiple), Application, (Chemotherapy, Long-term IV Infusion, Parenteral Nutrition) End-Use & Forecast, 2024 - 2032

Peripherally Inserted Central Catheters Market - By Product (Power Injected PICC, Conventional PICC, Neonatal PICC), Lumen (Single, Double, Multiple), Application, (Chemotherapy, Long-term IV Infusion, Parenteral Nutrition) End-Use & Forecast, 2024 - 2032

Peripherally inserted central catheters market size is set to register 9.6% CAGR during 2024-2032, driven by the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, which require prolonged administration of medications and fluids. As per WHO, in 2022, approximately 20 million new cancer cases were reported, resulting in 9.7 million mortalities. Peripherally inserted central catheters (PICCs) offer a reliable and less invasive alternative to traditional central venous catheters for providing patients with extended vascular access for weeks to months. This has led to their widespread adoption in hospitals and outpatient settings, where they facilitate the delivery of chemotherapy, parenteral nutrition, and antibiotics, among other therapies.

Innovations, such as antimicrobial coatings and radiopaque materials for accurate placement, and integrated flushing systems are improving infection control, visibility under imaging, and overall catheter management. The shift towards minimally invasive procedures and outpatient care models is also supporting the adoption of PICCs as they offer reduced complication rates and shorter hospital stays compared to traditional central lines.

The peripherally inserted central catheters industry is divided into product, lumen, application, end-use and region.

Based on product, the market size from the conventional PICC segment is poised to generate substantial revenue during 2024-2032 due to its established track record of safety, reliability, and familiarity among healthcare providers. Conventional PICCs are widely used in clinical settings for their versatility in delivering long-term intravenous therapies while minimizing the risks associated with more invasive central venous catheters. These devices are also equipped with features that facilitate precise placement, ease of maintenance, and compatibility with a wide range of medications and treatments.

Concerning end-use, the PICC market from the home-care settings segment is set to witness decent growth over the forecast period. This is backed by the strong need for offering patients a convenient and cost-effective option for receiving long-term intravenous therapy outside of traditional hospital settings. PICCs also provide a reliable method for administering medications, fluids, and parenteral nutrition directly into a central vein, thereby supporting patients with chronic conditions who require prolonged treatment at home.

Asia Pacific peripherally inserted central catheters industry size will surge significantly through 2032. Advancements in healthcare infrastructure and rising healthcare expenditure in the region are supporting the adoption of PICCs in hospitals and outpatient settings, where they facilitate the administration of chemotherapy, antibiotics, and parenteral nutrition. The growing elderly population in APAC countries, coupled with shifting healthcare policies that prioritize patient comfort and cost-efficiency, will further contribute to the market expansion.